Pharmacotherapy for social anxiety disorder: An update

Israel Journal of Psychiatry and Related Sciences

Volumn 46, Issue 1, 2009, Pages 53-61

  Van Ameringen, Michael ^a,b   Mancini, Catherine ^a,b   Patterson, Beth ^b   Simpson, William ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952571272     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. rd edition. Washington, D.C.: American Psychiatric Association, 1980.
2. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-288.
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62:617-627. (Pubitemid 40973437)
4. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-173.
5. Van Vliet IM, Denboer JA, Westenberg HGM. Psy-chopharmacological treatment of social phobia-a double-blind placebo-controlled study with fluvoxamine. Psychopharmacology (Berl) 1994;115:128-134.
6. Stein MB, Fyer AJ, Davidson JRT, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756-760.
7. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, Md.: U.S. Department of Health, 1976.
8. Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: A randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2007;10:263-274.
9. Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvox-amine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychophar-macol 2004;24:118-125.
10. rd edition: Revised. Washington, D.C.: American Psychiatric Association, 1987.
11. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia-a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-1371.
12. Liebowitz MR, Gorman JM, Fyer AJ, et al. Pharmaco-therapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988;49:252-257.
13. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158:275-281.
14. Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:785-792.
15. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial. JAMA 1998;280:708-713.
16. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M, Paroxetine Study Group. Paroxetine in social phobia. Br J Psychiatry 1999;175:120-126.
17. Allgulander C. Paroxetine in social anxiety disorder: A randomized placebo-controlled study. Acta Psychiatr Scand 1999;100:193-198.
18. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002;63:66-74.
19. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004;65:222-229.
20. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: A double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002;22:257-262.
21. Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder-randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005;186:222-226. (Pubitemid 40343816)
22. Van Ameringen M, Mancini C, Pipe B, Bennett M. Optimizing treatment in social phobia: A review of treatment resistance. CNS Spectr 2004;9:753-762.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4Th Edition. 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
24. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:488-496.
25. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, SAD Study Group. A randomized controlled trial of venla-faxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005;66:238-247.
26. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacol-ogy (Berl) 2005;177:280-288.
27. DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: Focus on nefazodone. J Clin Psychiatry 2002;63 Suppl 1:10-17.
28. Van Ameringen M, Mancini C, Oakman J, et al. Nefazo-done in the treatment of generalized social phobia: A randomized, placebo-controlled trial. J Clin Psychiatry 2007;68:288-295.
29. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55:1133-1141.
30. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
31. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia-a controlled-study. Arch Gen Psychiatry 1991;48:938-945.
32. Liebowitz MR, Heimberg RG, Schneier FR, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: Long-term outcome. Depress Anxiety 1999;10:89-98.
33. van Vliet IM, den Boer JA, Westenberg HG. Psycho-pharmacological treatment of social phobia: Clinical and. biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-29.
34. Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand 1995;92:351-358.
35. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997;17:255-260.
36. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998;172:70-77.
37. Noyes R, Jr., Moroz G, Davidson JR, et al. Moclobemide in social phobia: A controlled dose-response trial. J Clin Psychopharmacol 1997;17:247-254.
38. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997;247:71-80.
39. Stein DJ, Cameron A, Amrein R, Montgomery SA, Moclobemide Social Phobia Clinical Study Group. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 2002;17:161-170.
40. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psy-chopharmacol 1993;13:423-428.
41. Versiani M, Egidio N, Figueira I, Mendlowicz M, Marques C. Double-blind placebo controlled trial with bromazepam in social phobia. Jornal Brasilerio de Psiquiatria Marco 1997;46:167-171.
42. Van Ameringen M, Mancini C, Pipe B, Bennett M. An-tiepileptic drugs in the treatment of anxiety disorders. Drugs 2004;64:1-14.
43. Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004;65:1674-1678.
44. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004;65:1219-1222.
45. Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003;18:169-172.
46. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999;19:341-348.
47. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24:141-149.
48. Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: A placebo controlled pilot study. J Psychopharmacol 2005;19:551-553.
49. Moore NA, Rees G, Sanger G, Tye NC. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994;5:196-202.
50. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803-810.
51. Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: Results from an open-label study. J Clin Psychiatry 2005;66:540-542.
52. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: A pilot study. J Psychopharmacol 2002;16:365-368.
53. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65 Suppl 18:36-46.
54. Simpson HB, Schneier FR, Marshall RD, et al. Low dose selegiline (L-deprenyl) in social phobia. Depress Anxiety 1998;7:126-129.
55. Atmaca M, Tezcan E, Kuloglu M. An open clinical trial of reboxetine in the treatment of social phobia. J Clin Psychopharmacol 2003;23:417-419.
56. Emmanuel NP, Brawman-Mintzer O, Morton WA, et al. Bupropion-SR in treatment of social phobia. Depress Anxiety 2000;12:111-113.
57. Sheehan DV, Burnham DB, Iyengar MK, Perera P, Paxil CR Panic Disorder Study Group. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005;66:34-40.
58. Emmanuel NP, Lydiard RB, Ballenger JC. Treatment of social phobia with bupropion. J Clin Psychopharmacol 1991;11:276-277.
59. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazap-ine treatment of social phobia in women: A randomized, double-blind, placebo-controlled study. J Clin Psycho-pharmacol 2005;25:580-583.
60. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: A meta-analysis. J Clin Psychopharmacol 2001;21:311-324.
61. Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: A meta-analysis. Depress Anxiety 2003;18:29-40. (Pubitemid 37012933)
62. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 2007;8:175-187.
63. van der Linden GJ, Stein DJ, Van Balkom AJ. The efficacy of the selective serotonin inhibitors for social anxiety. disorder (social phobia): a meta analysis of randomized control trials. Int Clin Psychopharmacol 2000;15:S15-S23.
64. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31:767-771.
65. Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999;14:239-245.
66. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39:115-121.
67. Aarre TF. Phenelzine efficacy in refractory social anxiety disorder: A case series. Nord J Psychiatry 2003;57:313-315.
68. Simon NM, Hoge EA, Fischmann D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 2006;67:381-385.
69. Simon NM, Korbly NB, Worthington JJ, Kinrys G, Pollack MH. Citalopram for social anxiety disorder: An open-label pilot study in refractory and nonrefractory patients. CNS Spectr 2002;7:655-657.
70. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1725-1727.
71. Muller JE, Koen L, Seedat S, Stein DJ. Social anxiety disorder: Current treatment recommendations. CNS Drugs 2005;19:377-391.
72. Worthington JJ, 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11. (Pubitemid 40105542)
73. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: A randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003;64:1245-1249.
74. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with parox-etine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004;65:244-248.
75. Haug TT, Blomhoff S, Hellstrom K, et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 2003;182:312-318.
76. Lader M, Stender K, Burger V, Nil R. Efficacy and tol-erability of escitalopram in 12-and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19:241-248.
77. Connor KM, Davidson JR, Potts NL, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998;18:373-378.
78. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-360.
79. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study. Arch Gen Psychiatry 2002;59:1111-1118.
80. Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: The 12-to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003;6:317-323.
81. Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000;20:636-644.
82. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005;66:1270-1278.
83. Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: Some preliminary findings. Hum Psychopharmacol 2002;17:401-405.
84. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19:387-396.
85. Furmark T, Appel L, Michelgard A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005;58:132-142.